Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 803 participants.
Also called NCT01651780
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 803 participants
- Sponsor
- Registry
-
NCT01651780 -
2012-000632-26
-
- Other papers using this trial's data
- Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial
- Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Canada, France, Germany, Italy, Netherlands, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01651780. Randomized; no masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2015-06 (actual). Results posted on 2017-02-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH
- Acronym
- BRAVO 2/3
- Condition
- Severe Aortic Stenosis
- Condition
- Aortic Valve Replacement
- Intervention (Drug)
- Bivalirudin
- Intervention (Drug)
- Unfractionated Heparin
- Lead sponsor
- The Medicines Company
Record details
- Record id
cardio:ct-nct01651780- Content hash
ec6b224078b267e01adff4a2d996db35e61102ef99f46743ef13b60e08b5e7d6